Published online Jun 26, 2021. doi: 10.4252/wjsc.v13.i6.568
Peer-review started: March 8, 2021
First decision: March 29, 2021
Revised: April 7, 2021
Accepted: June 3, 2021
Article in press: June 3, 2021
Published online: June 26, 2021
Processing time: 110 Days and 0.1 Hours
The therapeutic value of mesenchymal stem cells (MSCs) for the treatment of infectious diseases and the repair of disease-induced tissue damage has been explored extensively. MSCs inhibit inflammation, reduce pathogen load and tissue damage encountered during infectious diseases through the secretion of antimicrobial factors for pathogen clearance and they phagocytose certain bacteria themselves. MSCs dampen tissue damage during infection by downregulating the levels of pro-inflammatory cytokines, and inhibiting the excessive recruitment of neutrophils and proliferation of T cells at the site of injury. MSCs aid in the regeneration of damaged tissue by differentiating into the damaged cell types or by releasing paracrine factors that direct tissue regeneration, differentiation, and wound healing. In this review, we discuss in detail the various mechanisms by which MSCs help combat pathogens, tissue damage associated with infectious diseases, and challenges in utilizing MSCs for therapy.
Core Tip: This review discusses the therapeutic benefits of utilizing mesenchymal stem cells (MSCs) to treat infectious diseases and repair tissue damage induced by the disease-causing infectious agents. The immunomodulatory and regenerative properties of MSCs are modulated by the inflammatory milieu generated by the disease and should be considered while utilizing MSCs for treatment.